JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Essex maintains an Overweight rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $14 to $15.
August 14, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Brian Essex maintains an Overweight rating on Cellebrite DI and raises the price target from $14 to $15.
The increase in the price target from $14 to $15 by a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for CLBT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100